1. Home
  2. PMN vs NDLS Comparison

PMN vs NDLS Comparison

Compare PMN & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$4.14

Market Cap

84.1M

Sector

Health Care

ML Signal

N/A

Logo Noodles & Company

NDLS

Noodles & Company

N/A

Current Price

$14.74

Market Cap

68.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
PMN
NDLS
Founded
2004
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
84.1M
68.7M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
PMN
NDLS
Price
$4.14
$14.74
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $42.75
N/A
AVG Volume (30 Days)
★ 333.3K
46.0K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $495,089,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 0.37
52 Week Low
$0.29
$0.47
52 Week High
$27.40
$19.00

Technical Indicators

Market Signals
Indicator
PMN
NDLS
Relative Strength Index (RSI) 33.11 55.14
Support Level N/A $12.83
Resistance Level $15.05 $15.51
Average True Range (ATR) 1.26 0.94
MACD -0.41 0.19
Stochastic Oscillator 14.81 78.54

Price Performance

Historical Comparison
PMN
NDLS

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

Share on Social Networks: